WO1999024568A1 - Proteine de liaison de l'hormone steroide - Google Patents
Proteine de liaison de l'hormone steroide Download PDFInfo
- Publication number
- WO1999024568A1 WO1999024568A1 PCT/JP1998/005010 JP9805010W WO9924568A1 WO 1999024568 A1 WO1999024568 A1 WO 1999024568A1 JP 9805010 W JP9805010 W JP 9805010W WO 9924568 A1 WO9924568 A1 WO 9924568A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- steroid hormone
- present
- dna
- binding protein
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
Definitions
- the present invention relates to steroid hormone binding proteins and their genes, and their production and use. Background art
- This protein is a protein purified from the microsomal fraction, has a hydrophobic region near the N-terminus, and has no homology with existing steroid receptors.
- Gene which is considered non-Bok homolog of PMBP to date "putative progesterone binding proteiry (LOCUS: HSPROGBIN s ⁇ click session number:. ACC Y12711) and the genes thought to homologue of rat" 25Dx "(LOCUS: RNU63 315, ⁇ click Session number: Ac U63315) has been isolated.
- bushy PMBP The properties of bushy PMBP have been well studied, and it has been reported that it binds not only to progesterone but also to corticosterone, cortisol, promegestone, and testosterone (Meyer C. (1996) Eur. J Biochem. 239, 726-731).
- An object of the present invention is to provide a novel steroid hormone-binding protein having homology to PMBP, a gene thereof, a method for producing them, and a use thereof. You.
- the present inventors have proposed a membrane-bound steroid-binding protein, PMBP (Falkenstein E, Meyer C, Eisen C, Scriba PC, Wehling M. (1996) Biochem Biophys Res. We found several ESTs that were presumed to be part of cDNA encoding a protein homologous to Conanun 229 (1), 86-89).
- PMBP Membrane-bound steroid-binding protein
- ESTs a membrane-bound steroid-binding protein
- a consensus sequence was extracted from the sequence information, and the polymerase chain reaction of a human gene was performed using a primer designed based on the consensus sequence.
- the present inventors succeeded for the first time in isolating a gene encoding a novel steroid hormone binding protein having homology with PMBP from humans.
- the present invention relates to a novel steroid hormone-binding protein having homology to PMBP and a gene thereof, and their production and use.
- a protein comprising an amino acid sequence in which one or more amino acids are substituted, deleted, and / or added in the amino acid sequence of SEQ ID NO: 4, and which has a binding activity to steroid hormone;
- (6) a method for producing the protein according to (1) or (2), comprising a step of culturing the transformant according to (5);
- the present invention relates to a membrane-bound progesterone binding protein (PMBP) (Falkenstein E, Meyer C, Eisen C, Scriba PC,
- PMBP membrane-bound progesterone binding protein
- hSMBP2 hSMBP2 cDNA
- amino acid sequence of the protein encoded by the cDNA is shown in SEQ ID NO: 4.
- FIG. 1 shows hSMBP2 and its homologous protein “Buyu PMBP”
- hSMBP2 Similar to “hSMBP2”, it is a human gene isolated by polymerase chain reaction using primers designed based on consensus sequences extracted from multiple ESTs having homology with “Bus PMBP”. For “hSMBPl”, the same gene has been registered on a database (Ac Y12711). As is evident from Fig. 1, hSMBP2 shows significant homology to PMBP, but has high overall homology
- homology is slightly lower except near the C-terminus, so it is considered to be a protein that belongs to the same family but binds a different steroid spectrum. It is.
- the steroid hormone binding protein of the present invention is considered to be a membrane-bound type, unlike a conventional receptor for regulating nuclear transcription. For this reason, it is considered that the hormone action is regulated by a mechanism different from that of the nuclear transcription regulation type receptor in the living body, and the steroid hormone binding protein of the present invention is targeted, for example, to regulate the nuclear transcription for steroid hormones. It is possible to develop drugs with few side effects using the difference in binding affinity with type receptors. In particular, since hSMBP2 is derived from humans, it is more effective in clinical development than proteins derived from other mammals such as bushu.
- the steroid hormone binding protein of the present invention can be prepared as a recombinant protein prepared using a genetic recombination technique or as a natural protein.
- a DNA encoding the steroid hormone-binding protein of the present invention (for example, a DNA having the nucleotide sequence of SEQ ID NO: 3) is inserted into an appropriate expression vector, and this is inserted into a host cell.
- It can be prepared by a method such as purification from a transformant obtained by introduction.
- a column using an antibody obtained by immunizing a small animal with the prepared recombinant protein is prepared, and a tissue, a cell (eg, For example, it can be prepared by a method such as performing affinity chromatography on an extract of testis, cancer cells, etc.) using the column.
- the present invention also includes proteins functionally equivalent to the “hSMBP2” protein.
- “functionally equivalent” means that the target protein has a steroid hormone-binding activity similarly to the “hSMBP2” protein.
- "Having binding activity to steroid hormones” means having at least one binding activity to steroid hormones.
- the binding activity to steroid hormone can be detected by, for example, a binding activity detection test using a commercially available tritium-labeled steroid hormone.
- a protein functionally equivalent to the “hSMBP2” protein can be prepared, for example, by mutating the amino acid sequence of the “hSMBP2” protein.
- a protein functionally equivalent to the “hSMBP2” protein by appropriately substituting an amino acid that does not affect its function can be isolated.
- a protein having an amino acid sequence in which one or more amino acids are substituted, deleted and / or added in the amino acid sequence of SEQ ID NO: 4, and which is functionally equivalent to the “hSMBP2” protein Included in the steroid hormone binding proteins of the invention.
- Methods for mutating the amino acid sequence of a protein include, for example, a site-directed mutagenesis system using PCI (GIBCO-BRL, Gaithersburg, Maryland), and a site-directed mutagenesis method using oligonucleotides (Kramer, W. and Fritz, HJ (1987) Methods in EnzymoL, 15: 350-367).
- the number of amino acids to be mutated is not particularly limited as long as the binding activity with steroid hormone is maintained, but is usually within 30 amino acids, preferably within 20 amino acids, and more preferably within 10 amino acids. And more preferably within 5 amino acids.
- the amino acid mutation in the protein may occur in nature, and the mutant protein thus generated is also included in the steroid hormone-binding protein of the present invention.
- Another method for preparing a protein functionally equivalent to the “hSMBP2” protein includes a method utilizing hybridization technology. That is, a person skilled in the art can use the well-known hybridization technology (Sambrook, J et al., Molecular Cloning 2nd ed. 9.47-9.58, Cold Spring Harbor Lab. Press, 1989) to prepare “hSMBP2”. Based on the DNA sequence encoding the protein (SEQ ID NO: 3) or a part thereof, a highly homologous DNA is isolated to obtain a protein functionally equivalent to the “hSMBP2” protein from the DNA be able to. Like this No .: 3 The DNA that hybridizes with the DNA consisting of the DNA sequence described in 3 above and is encoded by the DNA. “A protein functionally equivalent to the hSM BP2j protein is also included in the steroid hormone binding protein of the present invention.
- the stringency of a hybridization for isolating DNA encoding a functionally equivalent protein is usually about 42 ° C, 2xSSC, 0% SDS, preferably 50 ° C, 2xSSC. 0.13 ⁇ 4SDSj, more preferably “about 65 ° C., 2 ⁇ SSC, 0.1% SDSj. As the temperature is increased, isolation of DNA having higher homology is expected.
- the protein encoded by the DNA obtained by using the hybridization technique usually has high homology in amino acid sequence with the “hSMBP2” protein (SEQ ID NO: 4).
- High homology refers to homology of 40% or more, preferably 60% or more, and more preferably 80% or more. Sequence homology can be determined using the algorithm described in the literature (WiIlbur, W. J. and Lipman, D. J. Pro Natl. Acad. Sci. USA (1983) 80, 726-730).
- the present invention also relates to a DNA encoding the steroid hormone-binding protein of the present invention.
- the DNA of the present invention is not particularly limited as long as it can encode the steroid hormone-binding protein of the present invention, and includes cDNA, genomic DNA, chemically synthesized DNA, and the like.
- the cDNA can be prepared, for example, by preparing a primer based on the nucleotide sequence of SEQ ID NO: 3 and performing RT-PCR.
- Genomic DNA can be prepared, for example, by a plaque hybridization method using phage.
- the nucleotide sequence of the obtained DNA can be determined by a conventional method using a commercially available “dye terminator sequencing kit” (manufactured by Applied Biosystems) or the like.
- the present invention also relates to a vector into which the DNA of the present invention has been inserted.
- the vector into which the DNA of the present invention is inserted is not particularly limited, and a vector (for example, for gene therapy) for expressing the steroid hormone-binding protein of the present invention in a living body—an integrative protein
- a vector for example, for gene therapy for expressing the steroid hormone-binding protein of the present invention in a living body
- an integrative protein Various vectors are used depending on the purpose, such as a vector for preparing a vector.
- Examples of the vector used for expressing the steroid hormone binding protein of the present invention in a living body include, for example, adenovirus vector Factory pAdexLcwj and retrovirus vector “pZIPneo”.
- expression vector is particularly useful.
- Examples of the expression vector include, for example, pQE vector (manufactured by Qiagen, Hilden, Germany) when using E. coli, and rsp-QOlj (Stratagene when using yeast).
- pQE vector manufactured by Qiagen, Hilden, Germany
- rsp-QOlj Stratagene when using yeast
- insect cells "BAC-to-BAC baculovirus expression ion system j (GIBCO-BRL, Gaithersburg, Maryland), etc. is preferable.
- mammalian cells For example, when CH0 cells, COS cells, NIH3T3 cells, etc. are used, for example, rtacSwitch II expression systemj (Stratagene,! La Jolla, Califonia) is suitable. Insertion of the DNA of the present invention can be performed by a conventional method (for example, see “The Qiaexpressionist Handbook, Qiagen, Hidden, Ge Ma ny”).
- the present invention relates to a transformant carrying the DNA of the present invention in an expressible manner.
- the transformants of the present invention include those having the above-described vector into which the MA of the present invention has been inserted, those having the DNA of the present invention integrated in the host genome, and the like. As long as it is maintained so that it can be expressed.
- the cell into which the vector of the present invention is introduced is not particularly limited.
- a desired cell can be used as a target cell.
- Escherichia coli, yeast, animal cells, insect cells, etc. Etc. can be used.
- the introduction of the vector into the cell can be performed by, for example, an electroporation method, a calcium phosphate method, or the like. Separation and purification of the recombinant protein from the transformant prepared to produce the recombinant protein are carried out by a conventional method, for example, using the method described in the literature ⁇ The Qiaexpressionist handbook, Qiagen, Hilden, Germany j ''. It is possible.
- the present invention also relates to an antibody that binds to the steroid hormone-binding protein of the present invention.
- the form of the antibody of the present invention is not particularly limited, and includes a monoclonal antibody in addition to a polyclonal antibody. Also included are antisera obtained by immunizing egrets and the like with the steroidformon-binding protein of the present invention, polyclonal antibodies and monoclonal antibodies of all classes, and humanized antibodies and human antibodies obtained by genetic recombination. It is. It also includes a part of an antibody such as a single-chain antibody, a Fab fragment, and an F (ab ') 2 fragment.
- the antibody of the present invention can be prepared by the following method.
- a polyclonal antibody for example, first, a small animal such as a rabbit is immunized with the steroid hormone-binding protein of the present invention to obtain serum, which is then coupled to the steroid-binding protein of the present invention. By passing through a two-tea column, a fraction that recognizes only the steroid hormone-binding protein of the present invention is obtained. Next, immunoglobulin G or M can be prepared from this fraction by purifying it with protein A or protein G.
- a small animal such as a mouse is immunized with the steroid hormone-binding protein of the present invention, the spleen is excised from the mouse, and the spleen is ground to form cells.
- a clone that produces an antibody against the steroid hormone-binding protein of the present invention is selected from the fused cells (hybridomas) obtained by fusing with a reagent such as polyethylene glycol.
- the obtained hybridoma was transplanted into a mouse intraperitoneal cavity, ascites was collected from the mouse, and the obtained monoclonal antibody was subjected to, for example, ammonium sulfate precipitation, protein A, protein G column, It can be prepared by DEAE ion-exchange chromatography, or by purifying the steroid protein binding protein of the present invention using an affinity column to which the protein is coupled.
- the antibody of the present invention can be used for purification or detection of the steroid hormone-binding protein of the present invention, and can also be used as an agent for promoting or inhibiting signal transduction of the steroid hormone-binding protein of the present invention.
- a human antibody or a humanized antibody is effective in terms of immunogenicity.
- a human antibody can be prepared, for example, by immunizing a mouse in which the immune system has been replaced with a human, with the steroid hormone-binding protein of the present invention.
- Humanized antibodies can be prepared, for example, by cloning an antibody gene from a monoclonal antibody-producing cell, and grafting the antigen-determined site to an existing human antibody, such as the CDR graft method.
- the present invention also relates to a method for screening a compound that binds to the steroid hormone-binding protein of the present invention.
- the screening method of the present invention includes a step of bringing a test sample into contact with the steroid hormone-binding protein of the present invention and selecting a compound that binds to the steroid hormone-binding protein of the present invention.
- the test sample to be brought into contact with the steroid hormone-binding protein of the present invention is not particularly limited. For example, a cell extract, a library of synthetic low-molecular compounds, an expression product of a gene library, and a live synthetic peptide Rally and the like.
- the protein or gene that binds to the steroid protein binding protein of the present invention is, for example, a cell (for example, a testis tissue or a cell) that is expected to express the protein that binds to the steroid protein binding protein of the present invention.
- CDNA library using a phage vector (human gltl, ZAP, etc.) was prepared from ovarian tissue, etc., and expressed on LB-agarose.
- the protein is immobilized, the steroid hormone-binding protein of the present invention is purified as a fusion protein with a biotin label or a GST protein, and the purified protein is reacted with the above-mentioned filter to form a plaque expressing the protein to be bound.
- "Westwestern blotting method” detected with streptavidin or anti-GST antibody Skolnik EY, Margolis B, Mohammad i M, Lowenstein E, Fischer R, Drep ps A, Ullrich A, and Schlessinger J (1991) Cloning of PI3 kinase-associated ed p85 utilizing a novel method for expression / cloning of target protein s for receptor tyrosine kinases. Cell 65, 83-90).
- the steroid hormone-binding protein of the present invention is expressed in yeast cells as a fusion protein with the SRF binding region or GAL4 binding region, while the protein that binds to the steroid hormone-binding protein of the present invention is expressed.
- a cDNA library that is expressed in a form fused with the VP16 or GAL4 transcriptional activation region is prepared from the cells that are expected to be cloned, the cDNA library is introduced into the yeast cells, and a library is prepared from the positive clones detected. Isolate the derived cDNA (if the protein that binds to the steroid hormone binding protein of the present invention is expressed in yeast cells, the binding of the two activates the reporter gene, confirming a positive clone).
- Put the extract, empty It can also be prepared by purifying a protein that specifically binds to a protein. By analyzing the amino acid sequence of the obtained protein, synthesizing oligo MA based on the amino acid sequence, and screening a cDNA library using the DNA as a probe, it is also possible to obtain DNA encoding the protein. It is.
- a method of screening immobilized molecules by allowing a synthetic compound, a natural product bank, or a random phage peptide display library to act on the immobilized steroid hormone binding protein of the present invention, and a combinatorial chemistry technology Screening using high throughput (Wrighton NC; Farrell FX; Chang R Kashyap AK; Barbone FP; Mulcahy LS Johnson DL; Barrett RW; Joll iffe LK; Dower WJ., Small peptides as potent mimetics of the protein hormone erythropoietin, Science (UNITED STATES) Jul 26 1996, 273 p458-64 N Verdine GL., The combinatorial chemistry of nature.Nature (ENG LAND) Nov 7 1996, 384 pll-13, Hogan JC Jr., Directed combinatorial Chemis try.
- a compound that specifically binds to one of the two can be screened by performing the same screening using the steroid receptor for nuclear transcription-regulated steroid and the steroid hormone-binding protein of the present invention. is there. That is, a test sample is brought into contact with the steroid hormone-binding protein of the present invention and a nuclear-transcription-regulated steroid receptor, and the steroid-binding protein of the present invention or the nuclear-transcription-regulated steroid hormone is contacted. By selecting a compound that specifically binds to the receptor, it is possible to determine whether the steroid receptor binding protein of the present invention or the nuclear transcription-regulated steroid receptor is different from the receptor. Differentially binding compounds can be screened.
- Known nuclear transcription-regulating steroid hormone receptors used for this screening include, for example, progesterone receptor (Ac 189935), glucocorticoid receptor (Acc. 121069), andridine receptor (Acc. 105325), vitamins! ) Receptor (Acc. 340203), Mineral corticoid receptor (Ac 126885), Estrodidin receptor (Acc. 545757), Steroid hormone receptor ERM (Acc. 119560), Steroid hormone receptor ERR2 (Acc. .119561).
- progesterone receptor Ac 189935
- glucocorticoid receptor glucocorticoid receptor
- ridine receptor Acc. 105325
- vitamins! ) Receptor
- Mineral corticoid receptor Ac 126885
- Estrodidin receptor Acc. 545757
- Steroid hormone receptor ERM Acc. 119560
- Steroid hormone receptor ERR2 Acc. .119561
- Such a compound can be used as a compound for suppress
- the compound isolated by the screening method of the present invention when used as a drug, it can be formulated and used by a known pharmaceutical manufacturing method. For example, it is administered to a patient together with a pharmacologically acceptable carrier or vehicle (eg, saline, vegetable oils, suspensions, surfactants, stabilizers, etc.). Administration can be transdermal, intranasal, transbronchial, intramuscular, intravenous, or oral, depending on the nature of the compound.
- a pharmacologically acceptable carrier or vehicle eg, saline, vegetable oils, suspensions, surfactants, stabilizers, etc.
- Administration can be transdermal, intranasal, transbronchial, intramuscular, intravenous, or oral, depending on the nature of the compound.
- the compound to be isolated is DNA, it can be administered to the human body using the above-described vector expressed in vivo.
- the present invention relates to a DNA that specifically hybridizes with a DNA comprising the nucleotide sequence of SEQ ID NO: 3 (including its complementary strand) and has a chain length of at least 15 bases.
- Hybridize '' means that under normal hybridization conditions, preferably under stringent hybridization conditions, cross-hybridization significantly occurs with DNA encoding other proteins. None.
- Such a DNA can be used as a probe for detecting and isolating a DNA encoding the protein of the present invention, and as a primer for amplifying.
- the stringency for a specific hybridization can be determined by those skilled in the art by considering the temperature of the hybridization reaction, the reaction time, the concentration of the probe or primer, the length of the probe or primer, the salt strength, etc. It can be selected as appropriate.
- the “DNA having a chain length of at least 15 bases that specifically hybridizes with the DNA having the base sequence of SEQ ID NO: 3” of the present invention also includes, for example, antisense oligonucleotides and ribozymes. .
- Antisense oligonucleotides act on cells producing the protein of the present invention to bind to DNA or mAA encoding the protein, thereby inhibiting its transcription or translation or promoting mRNA degradation.
- the antisense oligonucleotide includes, for example, an antisense oligonucleotide that hybridizes at any position in the base sequence described in SEQ ID NO: 3.
- the antisense oligonucleotide is preferably an antisense oligonucleotide for at least 15 or more consecutive nucleotides in the nucleotide sequence of SEQ ID NO: 3. More preferably, the antisense oligonucleotide described above, wherein the consecutive at least 15 or more nucleotides include a translation initiation codon.
- antisense oligonucleotide derivatives and modifications thereof can be used.
- a modified product include a modified lower alkylphosphonate such as a methylphosphonate type or an ethylphosphonate type, a phosphorothioate-modified product or a phosphoramidite-modified product.
- Antisense oligonucleotides include not only those in which all nucleotides corresponding to nucleotides constituting a predetermined region of MA or mRNA are complementary, and those in which DNA or mRNA and oligonucleotide are described in SEQ ID NO: 3.
- a mismatch of one or more nucleotides may exist as long as the nucleotide sequence can be selectively and stably hybridized.
- Such DNA may be at least 70%, preferably at least 80 ° /, at least 15 contiguous nucleotide sequence regions. , More preferably 90 ° /. More preferably, those having 95% or more nucleotide sequence homology are shown.
- the antisense oligonucleotide of the present invention can be used as an external preparation such as a liniment or a poultice by mixing with an appropriate base material which is inactive against the oligonucleotide. If necessary, excipients, isotonic agents, solubilizing agents, stabilizing agents, preservatives, soothing agents, etc. are added to tablets, splinters, granules, capsules, ribosome capsules, and injections. , Lyophilized, liquid, nasal, etc. These can be prepared according to a conventional method. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a diagram in which the amino acid sequences of “hSMBP1” and “hSMBP2” proteins are aligned with the amino acid sequences of “pigPMBP” and “rat25dx” proteins.
- FIG. 2 is a diagram showing hydrophobic blocks of “hSMBP1” protein and “hSMBP2” protein.
- Fig. 3 is an electro-imaging image showing Northern blot analysis of “hSMBPl” and “hSMBP2”.
- 1 is lung
- 2 is small intestine
- 3 is muscle
- 4 is prostate
- 5 is testis
- 6 is ovary
- 7 is brain
- 8 is heart
- 9 is kidney
- 10 is spleen
- 1 is liver
- 1 2 indicates lymphocytes.
- the EST sequence which is a part of the cDNA encoding the protein having homology with PMBP (Progesterone Membrane Binding Protein), is collected from the Uni-gene of NCB I and aligned based on homology. The sequence was extracted. As a result, two It was found that they were separated into groups, and both were considered to be novel steroid-binding proteins. Therefore, they were named "hSMBPl” and “hSMBP2" (human Steroid Membrane Binding Protein) and analyzed as follows.
- primers were designed and synthesized.
- hSMBPl-l SEQ ID NO: 5 / 5′-AAGAATTCCTGCC TAGCGCGGCCCAACCTTTACT-3 ′
- hSMBP2 SEQ ID NO: 6 / 5′-GGGGATCCA AAAATAGATATACTTCCACTGMTG-3 ′
- hSMBP2-1 SEQ ID NO: 7/5, -ACGGATCCTGAAGGCCCCTGACTTTGGTTGTTTA-3 '
- hSMBPl Marathon-Ready cDNA, Kidney (Clontech) is used as a template, and “h SMBP1-1” and “hSMBP2” are used as primers, and the method recommended by the manufacturer (to uchdownPCR: 94 ° C) C for 1 minute, then 94 ° C for 30 seconds, 72 ° C for 4 minutes, 5 cycles, then 94 ° C for 30 seconds, 70 ° C for 4 minutes, 5 cycles, then 94 ° C for 20 seconds, 68 Amplification was performed using TaKaRa Ex Taq (Takara Shuzo) and an attached buffer instead of Advantage KlenTaq Polymerase Mix.
- hSMBPl-4 (SEQ ID NO: 9) 5'-GGTGAAGTCGCGCCGCTTGAG-3 '
- hSMBPl-5 (SEQ ID NO: 10) 5'-CTCAAGCGGCGCGACTTCACC-3 '
- hSMBPl-6 (SEQ ID NO: 11) 5 '-GGAAGCACTGAAGGATGA-3'
- hSMBPl-7 (SEQ ID NO: 12) 5, -CATCCTTCAGTGCTTCCT-3 '
- hSMBP2 Marathon-Ready cDNA, Placenta (Clontech) was used as a template, and the AP-1 primer (SEQ ID NO: 13/5 '-) attached to "hSMBP2-1" and Marathon-Ready cDNA CCATCCTAATACGACTCACTATAGGGC-3 ') and recommended by the manufacturer (touchdownPCR: 1 minute at 94 ° C, then 30 seconds at 94 ° C, 4 minutes at 72 ° C, 5 cycles, then 30 seconds at 94 ° C, 70 cycles 4 cycles at 5 ° C for 5 minutes, then 20 seconds at 94 ° C, 4 minutes at 25 ° C for 25 cycles, except for Advantage KlenTaq Polymerase Mix, but TaKaRa Ex Taq (Takara Shuzo) and the attached buffer Amplification reaction was carried out.
- Probe is plasmid ⁇ pC
- the nucleotide sequence of the obtained clone was determined using the following primer for sequencing synthesized using ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction Kit with Amplitaq DNA Polymerase FS and 377 A DNA Sequencer (Perkin-Elmer) (Table 2). ). Table 2 Primer name sequence
- GT10S1 (SEQ ID NO: 13) 5'-CTTTTGAGCAAGTTCAGCCT-3 '
- GT10A1 (SEQ ID NO: 14) 5'-AGAGGTGGCTTATGAGTATTTCTT-3 'hSMBP2-2 (SEQ ID NO: 15) 5'-GGAAATGCTGCTGAACGTG-3'
- hSMBP2-3 (SEQ ID NO: 16) 5'-GGGATGCCTCCAGAGGACT-3 '
- hS BP2-4 (SEQ ID NO: 17) 5, -CCACGTTCAGCAGCATTTC-3 '
- hSMBP2-5 (SEQ ID NO: 18) 5'-GGCATCCCTACCAGCAAAT-3 'As a result, three clones containing almost the entire length were obtained.
- rhSMBPlj was composed of 195 amino acids and estimated molecular weight was 21643.90, and "hSMBP2j was composed of 223 amino acids and estimated molecular weight was 23817.09.
- both proteins were membrane-bound.
- HSMBPl was found to be a family of steroid hormone-binding proteins. It showed a very high homology with BP and was considered to be a human homolog (Fig. 1).
- hSMBPl the same gene was registered by Heidelberg University (Ac Y12711). However, a comparison with that revealed that there was a difference of 2 bases in the coding region of “hSMBPl”, which was considered to be a PCR error.
- hSMBP2 is similar to “hSMBPl” in the vicinity of C, but is longer in the vicinity of the N-terminus than other proteins in the family, and has a lower homology, and is a membrane-bound protein that binds to other steroids. It was expected to be.
- Fig. 2 it was predicted that a hydrophobic region was present near the N-terminus, and that it was involved in localization to the microsomal fraction.
- hSMBPl Analysis of expression of “hSMBPl” and “hSMBP2” in various tissues
- hSMBPl probe used a fragment of about 600 bP obtained by treating pC0S-hSMBPlj with EcoRI-BamHI, and “hSMBP2” The probe used was an approximately 600 bp fragment obtained by EcoM-BamHI treatment of “pCH0-hSMBP2A”.
- hSMBPl was detected in all tissues examined, but was particularly strongly expressed in lung, small intestine, prostate, testis, ovary, brain, kidney, liver, and in muscle, heart, spleen, and lymphocytes. Expression was low (FIG. 3A).
- hSMBP2 was also detected in all examined tissues, and its expression was particularly high in ovaries, kidneys, liver and lymphocytes, and low in brain, heart and spleen (Fig. 3B).
- hSMBP2 cDNA was synthesized using the synthesized primers “hSMBP2-ATG” (SEQ ID NO: 19 / AAGAATTCCACCATGGCGGCTGGTGATGGGGACGT) and “hSMBP2MIC” (SEQ ID NO: 20). After performing PCR with / CCGAATTCAATGATGATGATGATGATGCAGATCCTCTTCTGAGATGAGTTTTTGTTCATCCTGTTTATTG TGATCCTT) and treating with restriction enzyme EcoRI, the plasmid was inserted into the EcoRI site of plasmid pC I-neo (promega) to obtain plasmid "pC I-hSMBP2MIC".
- This vector has a T7 promoter upstream of the N-terminus, and a C-terminus of the expressed protein with a MI C epitope and a HisTag consisting of six Hiss, which are recognized by anti-Myc antibody.
- the vector was subjected to in vitro translation according to the protocol of Single Tube Protein System 2 (manufactured by Novagen), followed by a heron anti-c-mic antibody (manufactured by Santa Cruz) and ProteinA Fast Flow (manufactured by Pharmacia). Immunoprecipitation was performed and eluted with SDS sample buffer.
- the immunoprecipitation supernatant and the obtained sample were subjected to SDS-PAGE, transferred to a PVDF membrane (manufactured by Bio-Rad), and conjugated with mouse anti-c-Myc monoclonal antibody and anti-mouse Color was developed using an IgG antibody.
- a band with an apparent molecular weight of about 32,000 was detected only in the lane of the immunoprecipitate in which the gene was correctly inserted. .
- the mobility about 6000 higher than the calculated molecular weight is considered to be the effect of the addition of HisTag.
- the steroid hormone-binding protein of the present invention is considered to be a membrane-bound type unlike a conventional receptor for nuclear transcription regulation, and regulates hormonal action in a living body by a mechanism different from that of a receptor for nuclear transcription regulation. Therefore, development of a drug with few side effects utilizing the difference in binding affinity of steroid hormone binding protein to the nuclear transcription regulatory receptor for steroid hormones, targeting the steroid hormone binding protein of the present invention And so on. As a result, it can be applied to the development of new therapeutic drugs related to immunity such as allergies and autoimmune diseases, and the development of therapeutic drugs for steroid-dependent malignant tumors.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98951720A EP1035204A4 (en) | 1997-11-07 | 1998-11-06 | STEROID HORMONE BINDING PROTEIN |
AU97620/98A AU9762098A (en) | 1997-11-07 | 1998-11-06 | Steroid hormone binding protein |
US09/565,808 US6432674B1 (en) | 1997-11-07 | 2000-05-05 | Steroid hormone binding protein |
US10/164,871 US7279284B2 (en) | 1997-11-07 | 2002-06-07 | Steroid hormone binding protein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/322376 | 1997-11-07 | ||
JP32237697 | 1997-11-07 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/565,808 Continuation-In-Part US6432674B1 (en) | 1997-11-07 | 2000-05-05 | Steroid hormone binding protein |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999024568A1 true WO1999024568A1 (fr) | 1999-05-20 |
Family
ID=18142966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/005010 WO1999024568A1 (fr) | 1997-11-07 | 1998-11-06 | Proteine de liaison de l'hormone steroide |
Country Status (4)
Country | Link |
---|---|
US (2) | US6432674B1 (ja) |
EP (1) | EP1035204A4 (ja) |
AU (1) | AU9762098A (ja) |
WO (1) | WO1999024568A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7504222B2 (en) | 2001-10-31 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7094742B2 (en) * | 2004-04-23 | 2006-08-22 | Jelmar, Llc | Hard surface cleaning compositions containing a sultaine and a mixture of organic acids |
US10316352B2 (en) * | 2008-05-13 | 2019-06-11 | Gen-Probe Incorporated | Methods of capturing a target nucleic acid for amplification and detection using an inactivatable target capture oligomer |
-
1998
- 1998-11-06 WO PCT/JP1998/005010 patent/WO1999024568A1/ja not_active Application Discontinuation
- 1998-11-06 AU AU97620/98A patent/AU9762098A/en not_active Abandoned
- 1998-11-06 EP EP98951720A patent/EP1035204A4/en not_active Ceased
-
2000
- 2000-05-05 US US09/565,808 patent/US6432674B1/en not_active Expired - Fee Related
-
2002
- 2002-06-07 US US10/164,871 patent/US7279284B2/en not_active Expired - Fee Related
Non-Patent Citations (5)
Title |
---|
BONALDO M DE F, LENNON G, SOARES M B: "NORMALIZATION AND SUBTRACTION: TWO APPROACHES TO FACILITATE GENE DISCOVERY", PCR METHODS & APPLICATIONS., COLD SPRING HARBOR LABORATORY PRESS., US, 1 January 1996 (1996-01-01), US, pages 791 - 806, XP002918419, ISSN: 1054-9803 * |
FALKENSTEIN E, ET AL.: "FULL-LENGTH CDNA SEQUENCE OF A PROGESTERONE MEMBRANE-BINDING PROTEIN FROM PROCINE VASCULAR SMOOTH MUSCLE CELLS", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 229, no. 01, 1 January 1996 (1996-01-01), AMSTERDAM, NL, pages 86 - 89, XP002918417, ISSN: 0006-291X, DOI: 10.1006/bbrc.1996.1761 * |
GERDES D, ET AL.: "CLONING AND TISSUE EXPRESSION OF TWO PUTATIVE STEROID MEMBRANE RECEPTORS", BIOLOGICAL CHEMISTRY, WALTER DE GRUYTER GMBH & CO., BERLIN, DE, vol. 379, no. 07, 1 July 1998 (1998-07-01), BERLIN, DE, pages 907 - 911, XP002918416, ISSN: 1431-6730 * |
MEYER C, ET AL.: "PURIFICATION AND PARTIAL SEQUENCING OF HIGH-AFFINITY PROGESTERONE-BINDING SITE(S) FROM PORCINE LIVER MEMBRANES", EUROPEAN JOURNAL OF BIOCHEMISTRY, WILEY-BLACKWELL PUBLISHING LTD., GB, vol. 239, no. 03, 1 January 1996 (1996-01-01), GB, pages 726 - 731, XP002918418, ISSN: 0014-2956, DOI: 10.1111/j.1432-1033.1996.0726u.x * |
See also references of EP1035204A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7504222B2 (en) | 2001-10-31 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
Also Published As
Publication number | Publication date |
---|---|
AU9762098A (en) | 1999-05-31 |
US20020177194A1 (en) | 2002-11-28 |
US7279284B2 (en) | 2007-10-09 |
EP1035204A1 (en) | 2000-09-13 |
EP1035204A4 (en) | 2003-06-25 |
US6432674B1 (en) | 2002-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wu et al. | Cloning and expression of the cDNA for human γ-glutamyl carboxylase | |
Lake et al. | Cloning of the rat and human prostaglandin F2α receptors and the expression of the rat prostaglandin F2α receptor | |
Wang et al. | Studies on mu and delta opioid receptor selectivity utilizing chimeric and site-mutagenized receptors. | |
JP2002505843A (ja) | システインリッチなレセプターであるtrain | |
JP2002517195A (ja) | 2871レセプターと名付けられたgタンパク質共役型レセプター | |
AU767010B2 (en) | Isoforms of human calcium sensing receptor | |
WO1999024568A1 (fr) | Proteine de liaison de l'hormone steroide | |
US6872558B1 (en) | Heparanase-2 a member of the heparanase protein family | |
JPH10234385A (ja) | 新規ヒトets科メンバーのelf3 | |
JP2002518008A (ja) | アンジオスタチン結合性タンパク質 | |
US6297359B1 (en) | Protein phosphatase 1 binding protein, R5 | |
US5846822A (en) | Nucleic acid molecules encoding PP32: a newly identified CD45-associated protein | |
US6627735B2 (en) | Islet cell antigen 1851 | |
US6472516B1 (en) | Progestin-regulated gene | |
WO2001038371A1 (fr) | Nouveau polypeptide glutamate arnt synthetase 58 d'origine humaine et polycnucleotide codant pour ce polypeptide | |
JP4307708B2 (ja) | エストロゲン受容体 | |
EP1148125B1 (en) | Human nucleoprotein having a ww domain and polynucleotide encoding the same | |
US20030232329A1 (en) | Novel human crh receptor-related receptor | |
US20030108906A1 (en) | Identification and use of molecules implicated in pain | |
US20020164785A1 (en) | Novel orphan receptors | |
JP2001509667A (ja) | Srcrドメイン含有タンパク質 | |
AU764484B2 (en) | Orphan cytokine receptor | |
JP2003259871A (ja) | 脳特異的発現を示す分泌タンパク質creg2とその利用 | |
EP1262487A1 (en) | Dna encoding squalene epoxidase promoter | |
JP2005505264A (ja) | 新規ヒトプロトンゲート調節チャンネル |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09565808 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998951720 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998951720 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWR | Wipo information: refused in national office |
Ref document number: 1998951720 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998951720 Country of ref document: EP |